Pipeline

Overview

Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications.

We are currently prioritizing four lead DUB target programs that are based on extensive research around the ~100 human DUBs and their market opportunities.

Our world-leading drug discovery and development platform gives us the opportunity to explore multiple additional DUB targets of relevance to other disease indications, both in-house and through partnerships with other pharmaceutical companies.

Several of our USP30 inhibitor programs are now approaching clinical development.

In-house programs

ResearchPreclinicalPhase I

DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Acute Kidney Injury

DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Idiopathic Pulmonary Fibrosis

DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Familial Parkinson’s Disease / Mitochondrial Disease

DUB program: DUB X
Rationale/target: Undisclosed
Therapeutic indication: Undisclosed

Partnered programs

ResearchPreclinicalPhase I

DUB program: AbbVie collaboration
Rationale/target: Undisclosed
Therapeutic indication: Alzheimer’s and Parkinson’s
Development stage: Undisclosed

DUB program: Pfizer collaboration
Rationale/target: Undisclosed
Therapeutic indication: Undisclosed
Development stage: Undisclosed

Mission Therapeutics © website by Instinctif Partners